Please login to the form below

SCLC

This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.

AZ scores FDA priority review for new Imfinzi fixed-dose regimen

Merck &Co’s checkpoint inhibitor Keytruda (pembrolizumab) currently holds much of the NSCLC market, although the drug failed to show benefit in SCLC when added to chemotherapy. ... The disappointing results in SCLC marred an otherwise dominant position

Latest news

GSK’s anti-BCMA drug leads crowded CHMP recommendations

into first-line extensive-stage small cell lung cancer (ES-SCLC), in combination with a choice of chemotherapies.
Tecentriq misses the mark in advanced ovarian cancer

However, its dominant setting is in small cell lung cancer (SCLC), a niche that Tecentriq had to itself until the recent approval of AstraZeneca’s Imfinzi (durvalumab) in front-line extensive ... The FDA approval for Imfinzi makes AZ’s drug the first
AZ’s Imfinzi gets US OK in small cell lung cancer, challenging Tecentriq

which is more common than SCLC – as well as bladder cancer and triple-negative breast cancer. ... Keytruda already has approval for third-line SCLC treatment after the failure of chemotherapy and has a phase 3 trial as a first-line treatment nearing
AZ’s Imfinzi plus tremelimumab combo misses again

AZ notes the CTLA4 inhibitor remains in clinical trials in combination with Imfinzi in NSCLC, SCLC, bladder cancer, head and neck cancer and liver cancer. ... SCLC last year and is still the only checkpoint inhibitor licensed for this use.
Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC

months in SCLC patients, compared to 10.3 months in the placebo group. ... SCLC accounts for around 15% of all lung cancer cases, with two-thirds of those diagnosed at the extensive stage of the disease.

More from news
Approximately 5 fully matching, plus 30 partially matching documents found.

Latest Intelligence

Deal Watch February 2017

triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. .
Deal Watch April 2016

Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.
Deal Watch November 2015

July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Improve clinical trials through patient journey mapping: Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...